Table 2 Clinical characteristics of study participants
From: Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana
Characteristics | N = 300 n, % |
|---|---|
Duration on TDF (study endpoint/censoring), median (IQR) years | 2.9 [2.3–3.4] |
Baseline CrCl rate, median (IQR), mL/min | 76.8 [58.3–105.4] |
WHO HIV stage | |
Stage I | 52 (17.3) |
Stage II | 76 (25.3) |
Stage III | 134 (44.7) |
Stage IV | 38 (12.7) |
HIV type | |
Type I | 284 (94.7) |
Type II | 16 (5.3) |
ART regimen administered | |
NNRTI-based | 291 (97.0) |
PI-based | 9 (3.0) |
Baseline CD4 count (cells/mm3) | |
< 150 | 134 (44.7) |
150–250 | 58 (19.3) |
> 250 | 108 (36.0) |
Adverse event | |
Present | 47 (15.7) |
Absent | 253 (84.3) |
Co-morbiditiesa | |
None | 220 (68.0) |
Pregnancy | 22 (7.3) |
Anaemia | 10 (3.3) |
Tuberculosis | 10 (3.3) |
Hypertension | 9 (3.0) |
Malaria | 9 (3.0) |
Pneumonia | 8 (2.7) |
Hepatitis | 7 (2.3) |
Cerebral toxoplasmosis | 6 (2.0) |
Urinary tract infection | 5 (1.7) |
Asthma | 2 (0.7) |
Diabetes | 2 (0.7) |
Achalasia | 1 (0.3) |
Deep vein thrombosis | 1 (0.3) |
Gouty arthritis | 1 (0.3) |
Psychosis | 1 (0.3) |
Co-medicationa | |
None | 260 (86.7) |
Antibiotic | 21 (7.0) |
Antihypertensive | 13 (4.3) |
Haematinic | 5 (1.7) |
Antiallergic | 3 (1.0) |
Anticoagulant | 2 (0.7) |
Antidiabetic | 2 (0.7) |
Antigout | 1 (0.3) |